Trials / Completed
CompletedNCT01928576
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Response Rate
Detailed description
Objective response rate to Nivolumab preceded by epigenetic priming. Response will be assessed by RECIST 1.1 criteria, baseline scans for this assessment will be the baseline scans done within 4 weeks of enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azacitidine | |
| DRUG | Entinostat | |
| DRUG | Nivolumab | |
| DRUG | CC-486 300 |
Timeline
- Start date
- 2013-11-06
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
- First posted
- 2013-08-26
- Last updated
- 2024-05-03
- Results posted
- 2024-05-03
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01928576. Inclusion in this directory is not an endorsement.